Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hodgkin Disease 9Neoplasms 3Melanoma 3Uveal Melanoma 1Melanoma, Cutaneous Malignant 1Lung Neoplasms 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Kidney Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Melanoma 1

Interventions

Nivolumab 5Cyclophosphamide 5pembrolizumab 4Ipilimumab 4fludarabine phosphate 3fludarabine 3Specimen Handling 3Radiosurgery 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Blood Specimen Collection 2trametinib 1tebentafusp 1ruxolitinib 1omipalisib 1olaparib 1lifileucel 1binimetinib 1belinostat 1avelumab 1Vorinostat 1Valproic Acid 1Tape Recording 1Sunitinib 1Spinal Puncture 1Practice Guidelines as Topic 1Pemetrexed 1Methods 1LY2940680 1Iodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Dacarbazine × 90 days × Clear all
NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Immunocore Ltd

Phase 2 Completed
378 enrolled 15 charts 1 FDA
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡